Clinical Trials Browser

Active not recruiting × OTHER × Melanoma × Clear all

NCT04478318 2026-03-10

Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma

Phase NA Active not recruiting

DermatologicLymphoidThoracic

Lung Neoplasms, Lymphoma, Melanoma

NCT03999749 2026-03-09

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Phase 2 Active not recruiting

71 enrolled 9 charts

Melanoma

NCT04020809 2026-03-09

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Phase 1 Active not recruiting

Melanoma

NCT00835133 2026-03-06

Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma

Active not recruiting

DermatologicGastrointestinal

Pancreatic carcinoma, familial, Melanoma, Neoplasms

NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Phase 2 Active not recruiting

DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT01644591 2026-03-05

Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06416085 2026-03-05

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

Phase 2 Active not recruiting

DermatologicLymphoidSarcoma

Endocrine Gland Neoplasms, Lymphoma, Melanoma, Osteosarcoma

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Phase 2 Active not recruiting

14 enrolled 9 charts

Melanoma

NCT02721459 2026-03-02

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1 Active not recruiting

Melanoma, Skin Neoplasms

NCT04990726 2026-02-27

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

Active not recruiting

Melanoma

NCT07428252 2026-02-25

Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma

Phase NA Active not recruiting

Melanoma

NCT05176470 2026-02-24

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Phase 1 Active not recruiting

Melanoma

NCT00338377 2026-02-23

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Phase 2 Active not recruiting

Melanoma, Meningeal Neoplasms

NCT04971499 2026-02-20

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

Phase 1/2 Active not recruiting

Melanoma

NCT05488483 2026-02-19

A Study of Tumor Imaging With Multispectral Optoacoustic Tomography

Active not recruiting

BreastDermatologic

Breast Neoplasms, Melanoma

NCT06237881 2026-02-18

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Phase 1/2 Active not recruiting

DermatologicHead & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms, Melanoma

NCT02816021 2026-02-17

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

Phase 2 Active not recruiting

Melanoma

NCT02231775 2026-02-13

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

Phase 2 Active not recruiting

Melanoma

NCT03699995 2026-02-13

MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

Phase NA Active not recruiting

Melanoma, Nevus, Pigmented

NCT05863052 2026-02-10

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Active not recruiting

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Gastrointestinal Neoplasms, Melanoma, Neoplasm Metastasis

NCT04866680 2026-02-09

PERCIMEL

Phase NA Active not recruiting

Melanoma

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Phase EARLY_PHASE1 Active not recruiting

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03420508 2026-02-05

Treating Patients With Melanoma and ALK Alterations With Ensartinib

Phase 2 Active not recruiting

Melanoma

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Phase EARLY_PHASE1 Active not recruiting

Melanoma, Skin Neoplasms

NCT04645680 2026-01-30

DIET

Phase 2 Active not recruiting

Uveal Melanoma, Melanoma

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Phase 2 Active not recruiting

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT07376317 2026-01-29

OTIMAS

Phase 2 Active not recruiting

Melanoma

NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Melanoma, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT03021460 2026-01-20

Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase 1 Active not recruiting

Melanoma

NCT02656706 2026-01-16

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

Phase 2 Active not recruiting

22 enrolled 10 charts

Melanoma

NCT00508443 2026-01-15

Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalLymphoidSarcomaThoracic

Urogenital Diseases, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Neoplasms, Sarcoma, Spinal Diseases, Spinal Neoplasms

NCT00582647 2026-01-15

Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract

Active not recruiting

DermatologicGastrointestinalSarcoma

Bile Duct Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms

NCT02724488 2026-01-08

SPECIAL

Active not recruiting

DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma

NCT03025256 2026-01-08

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Phase 1 Active not recruiting

DermatologicThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Meningeal Neoplasms, Nevus

NCT04616248 2026-01-07

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Phase 1 Active not recruiting

BreastDermatologicSarcoma

Bone Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Melanoma, Sarcoma, Osteosarcoma, Carcinoma, Merkel Cell

NCT05628883 2026-01-07

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Phase 1 Active not recruiting

Uveal Melanoma, Melanoma

NCT03929029 2026-01-05

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

Phase 1 Active not recruiting

11 enrolled 11 charts

Melanoma

NCT01266096 2025-12-31

PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

Phase NA Active not recruiting

Melanoma

NCT00539591 2025-12-23

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Phase 2 Active not recruiting

29 enrolled 28 charts

Melanoma

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

Phase 1/2 Active not recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01972347 2025-12-16

Neo Combi

Phase 2 Active not recruiting

Fever, Melanoma

NCT04207086 2025-12-16

Neo PeLe

Phase 2 Active not recruiting

Melanoma

NCT03131908 2025-12-15

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

Phase 1/2 Active not recruiting

Melanoma

NCT02374242 2025-12-10

ABC

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma, Neoplasm Metastasis

NCT05089370 2025-12-08

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

Phase 1/2 Active not recruiting

Melanoma

NCT02307630 2025-12-04

PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

Phase NA Active not recruiting

CNSDermatologicSarcoma

Melanoma, Neuroblastoma, Sarcoma

NCT02869217 2025-12-03

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Phase 1 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

NCT05282901 2025-11-24

PLUME

Phase 2 Active not recruiting

Uveal Melanoma, Melanoma, Neoplasm Metastasis